XIAMEN, April 9 (Xinhua) -Chinese scientists have extracted a medicinal compound from the natural herb, thunder god vine, which targets cell metabolism and could help tackle obesity. Celastrol, extracted from thunder god vine, and artemisinin, developed from sweet wormwood, are among five herbal compounds listed by the scientific journal Cell to have the most potential to treat illnesses where no cure has been discovered, such as cancer. The discovery of artemisinin won Chinese scientist Tu Youyou a Nobel Prize in 2015. The research team led by Zhang Xiaokun, professor with the College of Medicine at Xiamen University, found that celastrol from the thunder god vine could clear inflamed mitochondria from cells to alleviate inflammation. Mitochondria plays an integral role in cell death, immunity and inflammation. By affecting inflamed mitochondria, celastrol can help control cell metabolism. The team carried out the research on mice, and found that celastrol could effectively control weight increases in mice feeding on high fat food. The research paper was published in science journal Molecular Cell on April 6. Zhang said his team would continue to research how celastrol regulates metabolism to explore new drugs, with low toxicity and high efficiency, to help people lose weight. His research has been supported by the National Nature and Science Foundation and Xiamen South Sea Center. Like sweet wormwood, thunder god vine is native to China though it also grows in other East Asian countries. The herb has been used in traditional Chinese medicine for treating arthritis and autoimmune diseases. However, the whole plant is extremely toxic. It must undergo a lot of processing to reduce toxicity before being used in traditional medicine. In modern research, the plant has been used in clinical trials on AIDS treatment. Its compounds have been found to have the potential to treat joint pain and rheumatoid arthritis.
Cancer death rates in the United States have declined steadily over the years, thanks to improved screening guidelines and falling smoking rates, among other factors, according to a report released Thursday by the American Cancer Society. Since 1991, rates have fallen by 25 percent, resulting in more than 2.1 million deaths saved.
The trendy superfood ‘red dates’ from Asia kill cancer cells in the lab, new research suggests.
2012年12月29日讯 /生物谷BIOON/ --Merck、Roche、Sanofi等公司的研究人员采用新技术研发治疗癌症药物，以期获得新的突破。例如Sanofi公司正在研发一种针对p53蛋白的药物来治疗脂肪肉瘤。
In the last decade, available data indicate the rate of new cancer diagnoses fell by about 2 percent annually in men and remained the same in women, according to the report. Overall, the cancer death rate in men and women fell by about 1.5 percent each year.
2013年1月24日讯 /生物谷BIOON/ --罗氏今天宣布，FDA已批准将安维汀（Avastin，贝伐单抗）与基于氟尿嘧啶类药物伊立替康或奥沙利铂的化疗方案联合用药，用于转移性结直肠癌的治疗。这标志着现在患者可以选择使用Avastin 含伊立替康或奥沙利铂方案，用于转移性结直肠癌的一线治疗。该新适应症，是基于Avastin改善转移性结直肠癌治疗整体存活率而获得的第三个批准。（生物谷bioon.com）
“The continuing drops in the cancer death rate are a powerful sign of the potential we have to reduce cancer’s deadly toll,” Dr. Otis W. Brawley, chief medical officer of the ACS, said in a press release. “Continuing that success will require more clinical and basic research to improve early detection and treatment, as well as creative new strategies to increase healthy behaviors nationwide. Finally, we need to consistently apply existing knowledge in cancer control across all segments of the population, particularly to disadvantaged groups.”
英文原文：FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancerRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer . The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment).“The majority of people diagnosed with metastatic colorectal cancer receive Avastin plus chemotherapy as their initial treatment,” said Hal Barron, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “These people now have the option to continue with Avastin plus a new chemotherapy after their cancer worsens, which may help them live longer than changing to the new chemotherapy alone.”Avastin in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy is now indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen. The approval is based on positive results from the Phase III ML18147 study, which were presented at the 2012 American Society of Clinical Oncology annual meeting and showed that people who continued to receive an Avastin-based regimen after their cancer worsened lived longer than people who switched to chemotherapy alone.Avastin is the only biologic medicine approved by the FDA to treat people with mCRC in combination with intravenous 5FU-based chemotherapy as an initial treatment, as treatment for people whose cancer has worsened after chemotherapy alone, and now as a treatment for people whose cancer has worsened after initial treatment with an Avastin-based regimen. This is the third approval for Avastin in mCRC based on improved overall survival. Avastin is not indicated for adjuvant treatment of colon cancer.Avastin is approved in Europe in combination with fluoropyrimidine-based chemotherapy for the treatment of adult patients with metastatic carcinoma of the colon or rectum. The European product information has been updated based on the positive results of the Phase III ML18147 study with an implementation date of December 12, 2012 allowing people with mCRC who received Avastin plus chemotherapy as a first-line treatment to continue to receive Avastin plus chemotherapy after their cancer worsens as part of their second-line treatment.About the ML18147 studyML18147 was a randomised, open-label, phase III, multicentre, multinational trial evaluating the efficacy and safety profile of Avastin plus standard second-line chemotherapy in 820 patients with mCRC whose disease had progressed following Avastin plus standard first-line chemotherapy (irinotecan or oxaliplatin-based). Patients were randomised at progression to one of two treatment arms:Arm A: chemotherapy* plus Avastin (equivalent of 2.5 mg/kg i.v. per week)Arm B: chemotherapy* alone* Depending on the first-line chemotherapy backbone (fluoropyrimidine/irinotecan-based or fluoropyrimidine/oxaliplatin-based), the chemotherapy backbone was switched in the second-line setting.The risk of death was reduced by 19 percent for people who received Avastin in combination with standard chemotherapy in both the first- and second-line compared to those who received chemotherapy alone (HR=0.81, p=0.0057). Median overall survival was 11.2 months compared to 9.8 months.The risk of the cancer worsening or death (progression-free survival; PFS) was reduced by 32 percent (HR=0.68, p<0.0001). Median PFS was 5.7 months compared to 4.1 months.There was no significant difference in response rate between treatment arms.Overall survival and PFS were calculated from the time patients were randomised to the second-line treatment.Adverse events in ML18147 were consistent with those seen in previous pivotal trials of Avastin in mCRC.The primary endpoint of the study was overall survival measured from the time patients were randomized to the second-line treatment. The secondary efficacy endpoints of the study included PFS, overall response rate and safety profile.About colorectal cancerColorectal cancer is one of the most common cancers in the world, with over 1.2 million new cases diagnosed each year1 and it remains one of the biggest cancer killers in the world responsible for over 600,000 deaths globally each year.1About Avastin – over 8 Years of transforming cancer careWith the initial approval in the USA for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced cancer.Today, Avastin is continuing to transform cancer care through its proven survival benefit (overall survival and/or progression free survival) across several types of cancer. Avastin is approved in Europe for the treatment of advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, and is available in the US for the treatment of colorectal cancer, non-small cell lung cancer and kidney cancer. In addition, Avastin is approved in the US and almost 40 other countries worldwide for the treatment of patients with progressive glioblastoma following prior therapy. Avastin is approved in Japan for the treatment of the advanced stages of colorectal, non-small cell lung cancer and breast cancer. Avastin is the only anti-angiogenic therapy available for the treatment of these numerous advanced cancer types, which collectively cause over 2.5 million deaths each year.Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment today. Over one million patients have been treated with Avastin so far. A comprehensive clinical programme with more than 500 ongoing clinical trials is investigating the use of Avastin in over 50 tumour types.About Avastin – mode of actionAn independent blood supply is critical for a tumour to grow beyond a certain size and spread (metastasise) to other parts of the body. Tumours develop their own blood supply in a process called angiogenesis by releasing vascular endothelial growth factor – a key driver for tumour growth. Avastin is an antibody that precisely targets and inhibits VEGF for continuous tumour control. Precise VEGF inhibition by Avastin allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments with limited additional impact on the side effects of these therapies.About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.All trademarks used or mentioned in this release are protected by law.
Jujube fruits, which are known as red dates due to them looking similar to the Middle-Eastern staple, programme lung, breast and prostate cancer cells to commit suicide, a study published in the journal?Food & Function?found.
美国癌症学会的Dr. Otis Webb Brawley认为这种方法是癌症药物研发的未来。（生物谷Bioon.com）
The organization attributed declining prostate cancer deaths to the PSA blood test no longer being recommended. The test led to overdiagnosis of cancers, or disease that never need to be treated, according to the American Cancer Society. New lung cancer cases have dipped because of declining smoking rates, and the organization credited recent rapid decreases in colorectal cancer cases to expanded use of colonoscopies, which can remove pre-cancerous growths called poyps and prevent the disease.
However, the American Cancer Society wrote in its report, rates of new cancer cases remain varied by racial and ethnic groups, with African Americans suffering the largest burden. In 2014, their cancer death rate was about 15 percent higher than that of whites’. In children, cancer also remains a pressing health issue: The disease is the second most common cause of death in youths ages 1 to 14 years in the U.S., following accidents.
Red dates are thought to trigger cancer cell death by causing 'internal stress' in tumours, according to researchers from the Royal Society of Chemistry.
Cancer researchers have been rethinking the way new drugs are developed as investigations of new medicines focus more on molecular targets than on the organs where tumors originate. And this evolution in clinical development has crossed paths with the race to advance drugs that restore function of a protein to send cancer cells to their grave.
9159com金沙网站：Merck等公司采用新技术研究抗癌药，联合化疗治疗mCRC。The organization projects about 1.7 million new cancer cases and more than 600,000 cancer deaths in the U.S. in 2017. More than 200,000 new cases of rare cancers are expected to be diagnosed.
At the intersection are pharma companies such as Merck , Roche and Sanofi and smaller players such as Cellceutix seeking breakthroughs.
But the organization predicts that, among men, prostate, lung and colorectal cancers will account for about 42 percent of all newly diagnosed cancers in 2017. In women, breast, lung and colorectal cancers are projected to account for half of the predicted deaths in 2017. The organization expects breast cancer to account for 30 percent of all new cancer cases among women.
The results occurred after cancer cells were exposed to jujube in the lab. It is therefore unclear if the fruit helps to prevent or treat the disease in humans.
They have probed the role of the p53 protein in the death of cells with damaged DNA, and how cancer cells have found a variety of ways to stymie p53 function to stay alive and multiply. Yet pharma outfits have long hunted for drugs to revive the activity of the protein without much to show for their labors in human cancers.
Over the weekend The New York Times highlighted the progress of the three drug giants in the race to advance drugs that impact p53, which is incapacitated in a variety of common and rare cancers. Sanofi is advancing one of its compounds in a trial focused on patients with a rare fat-cell cancer known as liposarcoma, but the ubiquity of p53 inactivation across tumor types opens the door to testing individual drugs against cancers in many different organs at the same time.
Jujube fruits, which are used in Chinese medicine to treat insomnia, a loss of appetite and diarrhoea, are available in the UK for just ?1.99 for a 40g bag.
"This is a taste of the future in cancer drug development," said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society, in the Times article. "I expect the organ from which the cancer came from will be less important in the future and the molecular target more important."
Of course, behind many hot targets in cancer research are compelling stories of wiping out tumors, with the most compelling successes often found in mice, unfortunately. Cancer cells conspire in a variety of ways, including attachment of double minute 2 proteins to p53, to silence the kill switch.
The researchers exposed human lung, breast and prostate cancer cells to eight compounds found in jujube fruits.
Roche has already fallen short with compounds known as Nutlins (named after its Nutley, NJ, lab) that were designed to free p53 from the clutches of the double-minute protein. Tantalizing discoveries in the lab aren't often easy to translate into useful drugs. But Roche and others haven't given up on this target.
9159com金沙网站，Results suggest four of the compounds reduce the survival rate of these cells.
In addition, three red-date compounds trigger cancerous cells to kill themselves.
Internal stress caused by the compounds is thought to damage tumours' structures.
The researchers believe jujube extracts could be used in cancer treatments in traditional Chinese medicine.
They add, however, further research is required to determine how jujube fruit's compounds trigger cancer cell death.
Helen Wang, founder of Abakus Foods, previously told MailOnline: 'The Chinese saying goes "three jujube berries a day, keeps you young forever".
'It's not easy to find something that tastes good and is good for you at the same time.'